Advanced Enzyme Technologies Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹186Cr
- +20% YoY
- +11.4% QoQ
- Net profit
- ₹40Cr
- +14.3% YoY
- +48.1% QoQ
- Margin
- 30%
- −3 pp YoY
- +3 pp QoQ
Guidance rank: #81 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
The company targets double-digit growth over the longer run but is cautious about predicting exact figures due to product mix and market cycles. The company targets sustained double-digit growth over the medium to long term rather than very high short-term spikes.
From Advanced Enzyme Technologies Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets double-digit growth over the longer run but is cautious about predicting exact figures due to product mix and market cycles.
- Medium-term outlook expects maintaining or improving current momentum, with hopes to touch about 80% capacity utilization within 2 years before next capacity expansion.
- Focus remains on segments like Human Nutrition (notably Pharma and Probiotics) and Animal Nutrition, with some new products and biocatalyst applications under development.
- Regulatory changes favoring green chemistry and biocatalysts, especially in developed countries, could positively impact demand.
- Sales growth in probiotics is part of blends with enzymes; difficult to segregate but seen as a growth area.
2 more points from Advanced Enzyme Technologies Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Advanced Enzyme Technologies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company has been investing significantly in a new R&D facility at Nashik, with about INR48 crores already spent; this expense is currently under work in progress and not included in regular R&D expenditure.
- The new R&D center is expected to be commissioned by the last quarter of this fiscal year.
- Management is open to capacity expansions whenever capacity utilization approaches around 80%, which they hope to reach in about 2 years, indicating future capex in manufacturing capacity.
- There is mention of ongoing product development and research across various segments, suggesting continuous investment in innovation.
2 more points from Advanced Enzyme Technologies Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Advanced Enzyme Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Advanced Enzyme Technologies Ltd's call on order book
Create a free account to keep reading this call
Advanced Enzyme Technologies Ltd — Quarterly revenue & net profit
Advanced Enzyme Technologies Ltd Q1 FY26 results — key figures
| ₹ Cr | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 186 | 155 | +20% | 167 | +11.4% |
| Operating profit (EBITDA) | 56 | 51 | +9.8% | 46 | +21.7% |
| Operating margin | 30% | 33% | -3 pp | 27% | +3 pp |
| Profit before tax | 55 | 49 | +12.2% | 43 | +27.9% |
| Net profit (PAT) | 40 | 35 | +14.3% | 27 | +48.1% |
| EPS (₹) | 3.57 | 3.05 | +17% | 2.37 | +50.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹215 Cr, net profit ₹51 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Advanced Enzyme's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Laboratories (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Advanced Enzyme Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Advanced Enzyme Technologies Ltd Q1 FY26 results?
The company targets double-digit growth over the longer run but is cautious about predicting exact figures due to product mix and market cycles. The company targets sustained double-digit growth over the medium to long term rather than very high short-term spikes.
What is Advanced Enzyme Technologies Ltd share price analysis?
Advanced Enzyme Technologies Ltd currently shows a neutral. The stock trades at a P/E of 24.0 with a market cap of ₹3,726 Cr. Investors should review the full earnings analysis for detailed insights.
Is Advanced Enzyme Technologies Ltd planning capital expenditure?
The company has been investing significantly in a new R&D facility at Nashik, with about INR48 crores already spent; this expense is currently under work in progress and not included in regular R&D expenditure.
Keep Advanced Enzyme Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
